



February 9, 2021

Adimab Provides 2020 Update on Clinical Pipeline

***- 11 New Partner Programs Entered Clinical Development in 2020 -
- Total of 43 Clinical Programs Initiated to Date -***

Lebanon, New Hampshire – February 9, 2021 – Adimab, LLC, the global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, today announced that 11 new partner programs entered clinical development in 2020. This brings the total number of Adimab partner programs that have entered the clinic to 43. Partners initiating clinical programs in 2020 include Adagio, GlaxoSmithKline, Innovent, iTeos, Scholar Rock, Seattle Genetics, Surface Oncology, Takeda, and Tizona.

“This is the third year in a row that we have seen more than ten Adimab antibodies enter the clinic. With an additional three programs initiating pivotal studies in 2020 we are seeing a steady maturation of our portfolio,” said Tillman Gerngross, Chief Executive Officer and Co-Founder of Adimab. “Our partnering approach is built on the philosophy that we succeed when our partners succeed, and by providing them with the highest quality molecules we are increasing their probability of success in the clinic.”

In 2020, Adimab partners exercised 16 commercial licenses to advance programs into product development, bringing the total number of optioned programs to more than 75. Partners exercising commercial options in 2020 include Adagio, Biotheus, Cullinan, NextPoint, IASO, Magenta Therapeutics, Memorial Sloan Kettering, Scholar Rock, Surface Oncology and Takeda.

“Antibody discovery is cheap compared to the cost of manufacturing and clinical development. Why build an entire development program on a questionable foundation? Adimab generates therapeutic antibodies with exquisite specificity characteristics that other technologies simply cannot match. And the developability profiles of the antibodies we generate are unrivaled in the industry – no Adimab program has ever been terminated for developability reasons,” said Guy Van Meter, Chief Business Officer of Adimab.

About Adimab

Adimab is the leading provider of therapeutic antibody discovery and engineering technologies. This includes naïve discovery from synthetic libraries in yeast or B cells (mice and humans),

antibody engineering and optimization, multi-specific antibody engineering, and a portfolio of proprietary CD3 antibodies licensed non-exclusively for bispecific applications. Adimab focuses solely on its partners and not on developing an internal product pipeline. Since 2009, Adimab has partnered with over 80 pharmaceutical and biotechnology companies, generating more than 360 therapeutic programs, over 40 clinical programs, and its first approved product. The Adimab technology has been transferred and implemented at Biogen, GSK, Lilly, Merck, Novo Nordisk, and Takeda. Funded discovery partners include leading pharmaceutical companies, such as Boehringer Ingelheim, Bristol Myers Squibb, Novartis, Regeneron, Sanofi, Takeda and others. Adimab has also partnered with many early-stage venture-backed companies, including Amagma, Cygnal, Dragonfly, iOmx, NextPoint, Pliant, Tizona, TRex Bio and others, as well as mid-size public biopharmaceutical companies such as Acceleron, Alector, Cullinan Oncology, Five Prime, Innovent, Jounce, Mersana, Scholar Rock, Surface Oncology, and others.

Adimab's integrated antibody discovery and engineering platform provides unprecedented speed from antigen to purified, full-length human IgGs. Adimab offers fundamental advantages by delivering diverse panels of therapeutically relevant antibodies that meet the most demanding standards for affinity, epitope coverage, species cross-reactivity, and developability. Adimab enables its partners to rapidly expand their biologics pipelines through a broad spectrum of technology access arrangements. For more information, visit <http://www.adimab.com>.

Guy Van Meter
Chief Business Officer
Adimab, LLC
(603) 653-5775
guy.vanmeter@adimab.com